<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767738</url>
  </required_header>
  <id_info>
    <org_study_id>VGFTe-OD-1881</org_study_id>
    <nct_id>NCT03767738</nct_id>
  </id_info>
  <brief_title>Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe</brief_title>
  <official_title>A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine if the pre-filled syringe (PFS) supports
      successful preparation and accurate administration of an aflibercept injection.

      The secondary objective of the study is to assess ocular safety in the study eye.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">July 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of aflibercept injections successfully administered utilizing the PFS</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ocular adverse events (AEs) in the study eye</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all (ocular and non-ocular) serious adverse events (SAEs) in the study eye</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chorioretinal Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection (IAI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 - Initial patients Cohort 2 - Additional patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Aflibercept Injection (IAI)</intervention_name>
    <description>IAI prepared and administered with a pre-filled syringe (PFS)</description>
    <arm_group_label>Intravitreal Aflibercept Injection (IAI)</arm_group_label>
    <other_name>Aflibercept</other_name>
    <other_name>EYLEA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participants who have neovascular age-related macular degeneration (AMD), diabetic
             macular edema (DME), retinal vein occlusion (RVO), or diabetic retinopathy (DR) with
             diabetic macular edema (DME) in the study eye

        Key Exclusion Criteria:

          -  Evidence of active infectious blepharitis, keratitis, scleritis, or conjunctivitis in
             either eye

          -  Any active intraocular inflammation or infection in either eye or history of
             intraocular inflammation or infection after past intravitreal injection treatment
             (IVT) injections with any agent in either eye

          -  History of or any current indication of excessive bleeding and recurrent hemorrhages,
             including any prior excessive intraocular (including subconjunctival) bleeding or
             hemorrhages after IVT injection or intraocular procedures in either eye

          -  Any intraocular surgery in the study eye at any time during the past 3 months

          -  Current systemic infectious disease or a therapy for active infectious disease

          -  Pregnant or breastfeeding women

        Note: Other inclusion/ exclusion apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

